Free Trial
NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

Verastem logo
$4.05 +0.14 (+3.58%)
(As of 11/26/2024 ET)

About Verastem Stock (NASDAQ:VSTM)

Key Stats

Today's Range
$3.92
$4.24
50-Day Range
$2.61
$4.46
52-Week Range
$2.10
$14.22
Volume
781,447 shs
Average Volume
596,581 shs
Market Capitalization
$180.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Buy

Company Overview

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
58th Percentile Overall Score

VSTM MarketRank™: 

Verastem scored higher than 58% of companies evaluated by MarketBeat, and ranked 422nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verastem has only been the subject of 4 research reports in the past 90 days.

  • Read more about Verastem's stock forecast and price target.
  • Earnings Growth

    Earnings for Verastem are expected to grow in the coming year, from ($3.16) to ($2.94) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verastem is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verastem is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verastem has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Verastem's valuation and earnings.
  • Percentage of Shares Shorted

    6.06% of the float of Verastem has been sold short.
  • Short Interest Ratio / Days to Cover

    Verastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verastem has recently increased by 0.82%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Verastem does not currently pay a dividend.

  • Dividend Growth

    Verastem does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.06% of the float of Verastem has been sold short.
  • Short Interest Ratio / Days to Cover

    Verastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verastem has recently increased by 0.82%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Verastem has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Verastem this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,271.00 in company stock.

  • Percentage Held by Insiders

    Only 2.20% of the stock of Verastem is held by insiders.

  • Percentage Held by Institutions

    88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verastem's insider trading history.
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Stock News Headlines

Verastem Inc. Reports Increased Operating Expenses and Net Loss
The Great AI-Energy Collision
The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector.
Verastem (NASDAQ:VSTM) Cut to "Sell" at StockNews.com
Analysts Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $14.57
RBC Capital Reaffirms Their Buy Rating on Verastem (VSTM)
See More Headlines

VSTM Stock Analysis - Frequently Asked Questions

Verastem's stock was trading at $8.14 at the beginning of 2024. Since then, VSTM shares have decreased by 50.2% and is now trading at $4.05.
View the best growth stocks for 2024 here
.

Verastem, Inc. (NASDAQ:VSTM) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.11.

Verastem shares reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Verastem's top institutional shareholders include Stonepine Capital Management LLC (2.94%), Geode Capital Management LLC (2.00%), State Street Corp (0.95%) and Walleye Capital LLC (0.49%). Insiders that own company stock include Dan Paterson, Brian M Stuglik, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends
.

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/06/2024
Today
11/26/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/13/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+203.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-87,370,000.00
Pretax Margin
-934.54%

Debt

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$2.27 per share

Miscellaneous

Free Float
43,528,000
Market Cap
$183.38 million
Optionable
Optionable
Beta
0.14
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VSTM) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners